Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 5,812.58 | 5,510.22 | 5,776.93 | 7,944.04 | 6,965.99 |
| Operating profit | 538.16 | 722.88 | 750.54 | 2,171.97 | 1,499.77 |
| Interest | 27.05 | 8.45 | 8.50 | 16.85 | 38.77 |
| Gross profit | 605.68 | 1,259.09 | 868.36 | 2,329.32 | 1,659.59 |
| EPS (Rs) | 4.89 | 17.78 | 7.04 | 25.88 | 19.53 |
Half yearly
results in details
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 94.57 | 544.66 | 126.32 | 174.20 | 198.59 |
| Stock adjustment | -81.17 | 28.86 | 16.65 | -19.35 | -191.82 |
| Raw material | 3,201.56 | 2,838.27 | 2,945.66 | 3,624.63 | 3,545.99 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 816.81 | 779.99 | 820.05 | 851.31 | 809.85 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,337.22 | 1,140.22 | 1,244.03 | 1,315.48 | 1,302.20 |
| Provisions made | - | - | - | - | - |
| Depreciation | 211.85 | 202.42 | 212.83 | 239.93 | 237.40 |
| Taxation | 107.04 | -60.01 | 242.78 | 573.17 | 278.08 |
| Net profit / loss | 286.79 | 1,041.97 | 412.75 | 1,516.22 | 1,144.11 |
| Extra ordinary item | - | -74.71 | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 9.26 | 13.12 | 12.99 | 27.34 | 21.53 |
| GPM (%) | 10.25 | 20.79 | 14.71 | 28.69 | 23.16 |
| NPM (%) | 4.85 | 17.21 | 6.99 | 18.68 | 15.97 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis